Experimental CAR-T therapy targets tough blood cancers in small early trial
NCT ID NCT05895994
First seen Feb 03, 2026 · Last updated May 04, 2026 · Updated 15 times
Summary
This early-phase study tested a new treatment called RD13-02, which uses a patient's own immune cells modified to attack cancer cells with a specific marker (CD7). It involved just 2 people with blood cancers like T-cell acute lymphoblastic leukemia that had come back or not responded to other treatments. The main goal was to check if the treatment is safe and how long the modified cells stay in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.